Dependency on a ventilator at 4 weeks · patients with Guillain‐Barré syndrome
Plasma exchange probably leads to lower dependency on a ventilator at 4 weeks compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
Full muscle strength recovery at 1 year · patients with Guillain‐Barré syndrome
Plasma exchange probably leads to higher full muscle strength recovery at 1 year compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] · patients with Guillain‐Barré syndrome
Plasma exchange probably leads to higher relapses at 1 year compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
Deaths at 1 year · patients with Guillain‐Barré syndrome
Plasma exchange showed no clear difference in deaths at 1 year compared with sham exchange or supportive treatment (high certainty).
1 finding from 1 review
Severe infection · patients with Guillain‐Barré syndrome
Plasma exchange showed no clear difference in severe infection compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
1Trials were not blinded. · patients with Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Intervention not reported
Change in disability after one year · people with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in grip strength · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Sleeplessness · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to lower sleeplessness compared with oral prednisolone (low certainty).
1 finding from 1 review
Moon facies · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to lower moon facies compared with oral prednisolone (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in impairment after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Intervention not reported
Change in impairment after 12 weeks (including those who did not complete the study) NIS (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Intervention not reported
Number of participants improved after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
It is very uncertain whether the intervention changes number of participants improved after 12 weeks (excluding those who… (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants improved after 12 weeks (including those who did not complete the study) NIS (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy
It is very uncertain whether the intervention changes number of participants improved after 12 weeks (including those who… (very low certainty).
1 finding from 1 review
Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review